CA3000765A1 - Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques - Google Patents
Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques Download PDFInfo
- Publication number
- CA3000765A1 CA3000765A1 CA3000765A CA3000765A CA3000765A1 CA 3000765 A1 CA3000765 A1 CA 3000765A1 CA 3000765 A CA3000765 A CA 3000765A CA 3000765 A CA3000765 A CA 3000765A CA 3000765 A1 CA3000765 A1 CA 3000765A1
- Authority
- CA
- Canada
- Prior art keywords
- value
- gradient
- values
- voi
- para
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005070 sampling Methods 0.000 title claims description 93
- 230000007246 mechanism Effects 0.000 title claims description 30
- 238000000034 method Methods 0.000 claims abstract description 270
- 210000001519 tissue Anatomy 0.000 claims abstract description 166
- 230000007170 pathology Effects 0.000 claims abstract description 117
- 238000005259 measurement Methods 0.000 claims abstract description 95
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 76
- 201000010099 disease Diseases 0.000 claims abstract description 75
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 50
- 238000009792 diffusion process Methods 0.000 claims description 82
- 238000003384 imaging method Methods 0.000 claims description 82
- 210000000988 bone and bone Anatomy 0.000 claims description 70
- 230000006870 function Effects 0.000 claims description 53
- 210000004556 brain Anatomy 0.000 claims description 43
- 238000012935 Averaging Methods 0.000 claims description 30
- 238000009826 distribution Methods 0.000 claims description 30
- 230000000875 corresponding effect Effects 0.000 claims description 27
- 210000005166 vasculature Anatomy 0.000 claims description 27
- 238000010801 machine learning Methods 0.000 claims description 25
- 210000004185 liver Anatomy 0.000 claims description 24
- 239000000090 biomarker Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 21
- 230000002596 correlated effect Effects 0.000 claims description 21
- 238000004422 calculation algorithm Methods 0.000 claims description 19
- 230000005284 excitation Effects 0.000 claims description 18
- 230000010412 perfusion Effects 0.000 claims description 17
- 230000003902 lesion Effects 0.000 claims description 16
- 230000036962 time dependent Effects 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 13
- 230000001537 neural effect Effects 0.000 claims description 13
- 238000012805 post-processing Methods 0.000 claims description 11
- 238000012937 correction Methods 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 210000005013 brain tissue Anatomy 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 8
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 5
- 206010061728 Bone lesion Diseases 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 230000000971 hippocampal effect Effects 0.000 claims description 5
- 238000002075 inversion recovery Methods 0.000 claims description 5
- 230000006996 mental state Effects 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 238000006213 oxygenation reaction Methods 0.000 claims description 4
- 238000010176 18-FDG-positron emission tomography Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 3
- 230000002784 sclerotic effect Effects 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 34
- 238000003745 diagnosis Methods 0.000 abstract description 23
- 238000012544 monitoring process Methods 0.000 abstract description 17
- 238000001727 in vivo Methods 0.000 abstract description 16
- 238000012512 characterization method Methods 0.000 abstract description 11
- 230000002829 reductive effect Effects 0.000 abstract description 11
- 208000020084 Bone disease Diseases 0.000 abstract description 7
- 208000012902 Nervous system disease Diseases 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 238000012307 MRI technique Methods 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 description 100
- 239000000523 sample Substances 0.000 description 57
- 238000011161 development Methods 0.000 description 54
- 230000018109 developmental process Effects 0.000 description 53
- 230000004044 response Effects 0.000 description 39
- 230000001965 increasing effect Effects 0.000 description 33
- 238000002595 magnetic resonance imaging Methods 0.000 description 33
- 208000024827 Alzheimer disease Diseases 0.000 description 32
- 206010012289 Dementia Diseases 0.000 description 30
- 210000000056 organ Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 29
- 239000003550 marker Substances 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 208000019423 liver disease Diseases 0.000 description 21
- 230000007423 decrease Effects 0.000 description 20
- 238000002597 diffusion-weighted imaging Methods 0.000 description 20
- 208000010392 Bone Fractures Diseases 0.000 description 18
- 238000002592 echocardiography Methods 0.000 description 18
- 206010017076 Fracture Diseases 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 210000001320 hippocampus Anatomy 0.000 description 17
- 230000001054 cortical effect Effects 0.000 description 16
- 206010061818 Disease progression Diseases 0.000 description 15
- 230000037180 bone health Effects 0.000 description 15
- 230000005750 disease progression Effects 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000002491 angiogenic effect Effects 0.000 description 13
- 238000012045 magnetic resonance elastography Methods 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000010363 phase shift Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 206010016654 Fibrosis Diseases 0.000 description 11
- 239000002872 contrast media Substances 0.000 description 11
- 238000002598 diffusion tensor imaging Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 9
- 238000013425 morphometry Methods 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 239000013626 chemical specie Substances 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- 210000001353 entorhinal cortex Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 230000002123 temporal effect Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 210000004885 white matter Anatomy 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000004088 simulation Methods 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 210000003710 cerebral cortex Anatomy 0.000 description 6
- 230000001010 compromised effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000009021 linear effect Effects 0.000 description 6
- 230000005415 magnetization Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000004088 microvessel Anatomy 0.000 description 6
- 230000003562 morphometric effect Effects 0.000 description 6
- 210000000478 neocortex Anatomy 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000006999 cognitive decline Effects 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000007792 alzheimer disease pathology Effects 0.000 description 4
- 238000005311 autocorrelation function Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 210000003618 cortical neuron Anatomy 0.000 description 4
- 208000017004 dementia pugilistica Diseases 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000007171 neuropathology Effects 0.000 description 4
- 230000001009 osteoporotic effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000001423 neocortical effect Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000010408 sweeping Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000032665 vasculature development Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000016247 Soft tissue disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 230000009787 cardiac fibrosis Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 208000036449 fibrotic liver disease Diseases 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000009022 nonlinear effect Effects 0.000 description 2
- 239000000101 novel biomarker Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000000264 spin echo pulse sequence Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 230000010351 cardiac pulsation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000005654 stationary process Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/0036—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room including treatment, e.g., using an implantable medical device, ablating, ventilating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/4818—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/4833—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy using spatially selective excitation of the volume of interest, e.g. selecting non-orthogonal or inclined slices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/561—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/565—Correction of image distortions, e.g. due to magnetic field inhomogeneities
- G01R33/56509—Correction of image distortions, e.g. due to magnetic field inhomogeneities due to motion, displacement or flow, e.g. gradient moment nulling
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- High Energy & Nuclear Physics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Signal Processing (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Les modes de réalisation de l'invention portent sur un procédé pour l'acquisition de données RM à des résolutions pouvant descendre jusqu'à des dizaines de microns pour l'application en diagnostic in vivo et la surveillance d'une pathologie pour laquelle des changements de fines textures de tissu peuvent être utilisés comme marqueurs de l'apparition et de la progression d'une maladie. Les maladies osseuses, les tumeurs, les maladies neurologiques et les maladies impliquant la croissance et/ou la destruction des fibres sont toutes des pathologies cibles. En outre, la technique peut être utilisée dans n'importe quel système biologique ou physique pour une caractérisation très haute résolution d'une morphologie à petite échelle. Le procédé concerne l'acquisition rapide de valeurs sélectionnées dans l'espace k, avec plusieurs acquisitions successives de valeurs k individuelles prises sur une échelle de temps de l'ordre de la microseconde, dans un volume de tissu défini et la combinaison subséquente des multiples mesures de manière à augmenter au maximum le rapport signal/bruit. Le volume d'acquisition réduit et l'acquisition uniquement des valeurs sélectionnées dans l'espace k le long de directions sélectionnées permettent une bien meilleure résolution in vivo que ce qu'il est possible d'obtenir avec les techniques d'IRM actuelles.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238121P | 2015-10-07 | 2015-10-07 | |
| US62/238,121 | 2015-10-07 | ||
| US201662302577P | 2016-03-02 | 2016-03-02 | |
| US62/302,577 | 2016-03-02 | ||
| US15/167,828 US9664759B2 (en) | 2014-09-01 | 2016-05-27 | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling |
| US15/167,828 | 2016-05-27 | ||
| US201662382695P | 2016-09-01 | 2016-09-01 | |
| US62/382,695 | 2016-09-01 | ||
| PCT/US2016/056147 WO2017062882A1 (fr) | 2015-10-07 | 2016-10-07 | Échantillonnage sélectif pour évaluer des fréquences spatiales structurales avec des mécanismes de contraste spécifiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3000765A1 true CA3000765A1 (fr) | 2017-04-13 |
| CA3000765C CA3000765C (fr) | 2024-01-23 |
Family
ID=58488603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3000765A Active CA3000765C (fr) | 2015-10-07 | 2016-10-07 | Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3359034A4 (fr) |
| JP (1) | JP6906507B2 (fr) |
| CN (1) | CN108366753B (fr) |
| AU (1) | AU2016334250B2 (fr) |
| CA (1) | CA3000765C (fr) |
| WO (1) | WO2017062882A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110958854A (zh) * | 2017-05-24 | 2020-04-03 | 生物质子股份有限公司 | 用于评估具有指定对比度机制的结构空间频率的选择性采样 |
| JP7227953B2 (ja) * | 2017-07-06 | 2023-02-22 | バイオプロトニクス インコーポレイテッド | Ｎｍｒ分光法を用いて組織の標的領域内の成分テクスチャ要素の化学種を同定する組織テクスチャ測定方法 |
| CN110943817A (zh) * | 2018-09-21 | 2020-03-31 | 中兴通讯股份有限公司 | 波束失败恢复方法及装置 |
| AU2019384147A1 (en) * | 2018-11-20 | 2021-06-17 | Bioprotonics, Inc. | A method to measure tissue texture using NMR spectroscopy with VOI length in an analysis direction defined by receiver bandwidth |
| WO2020120941A1 (fr) * | 2018-12-10 | 2020-06-18 | Oxford University Innovation Limited | Imagerie cérébrale |
| WO2020125806A1 (fr) | 2018-12-17 | 2020-06-25 | Shanghai United Imaging Intelligence Co., Ltd. | Systèmes et procédés de segmentation d'image |
| CN109754394B (zh) * | 2018-12-28 | 2021-02-23 | 上海联影智能医疗科技有限公司 | 三维医学图像处理装置及方法 |
| WO2020136571A1 (fr) * | 2018-12-26 | 2020-07-02 | Analytics For Life Inc. | Procédés et systèmes de configuration et d'utilisation de réseaux neuronaux dans la caractérisation de systèmes physiologiques |
| EP3918987A4 (fr) | 2019-01-31 | 2022-09-07 | FUJIFILM Corporation | Modèle appris, procédé d'apprentissage, et programme, et dispositif d'acquisition d'informations médicales, procédé, et programme |
| CN110322408A (zh) * | 2019-06-11 | 2019-10-11 | 浙江大学 | 基于云平台的多中心磁共振图像自动质量控制方法 |
| CN110599447B (zh) * | 2019-07-29 | 2023-10-20 | 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) | 一种肝癌病灶数据的处理方法、系统和存储介质 |
| CN110501664B (zh) * | 2019-08-23 | 2021-07-16 | 苏州朗润医疗系统有限公司 | 磁共振波谱相位校正方法及应用该方法的磁共振成像系统 |
| TWI754858B (zh) | 2019-11-21 | 2022-02-11 | 國立中央大學 | 光學斷層造影系統及造影方法 |
| US11085979B1 (en) * | 2020-02-24 | 2021-08-10 | Uih America, Inc. | System and method for magnetic resonance imaging with radial sampling of k-space |
| CN111803068A (zh) * | 2020-08-21 | 2020-10-23 | 上海中医药大学附属曙光医院 | 一种基于虚拟磁共振弹性成像的无创评估肝纤维化的方法 |
| CN112184845B (zh) * | 2020-09-02 | 2023-05-05 | 东软医疗系统股份有限公司 | 弥散加权图像重建模型的生成方法及装置 |
| CN112304811B (zh) * | 2020-10-22 | 2023-02-03 | 无锡鸣石峻致医疗科技有限公司 | 一种对运动不敏感的低场核磁共振表观扩散系数测量方法 |
| CN112958840B (zh) * | 2021-02-10 | 2022-06-14 | 西南电子技术研究所（中国电子科技集团公司第十研究所） | 精密零件加工削力信号自动分段方法 |
| CN113156350B (zh) * | 2021-03-25 | 2022-07-19 | 华南理工大学 | 无创光不透明微米级活体组织磁共振断层成像方法及系统 |
| WO2023055471A1 (fr) * | 2021-09-29 | 2023-04-06 | The Johns Hopkins University | Identification automatisée de grappes de coefficients de diffusion apparents à hyperintensité pour une thérapie thermique interstitielle laser guidée par irm |
| CN116509453B (zh) * | 2023-06-29 | 2023-09-01 | 南京科进实业有限公司 | 一种基于超声波的胫骨骨密度检测系统及方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63130056A (ja) * | 1986-11-21 | 1988-06-02 | 旭化成株式会社 | 部分選択核磁気共鳴情報導出方法 |
| JP3393895B2 (ja) * | 1993-09-13 | 2003-04-07 | 株式会社東芝 | 磁気共鳴映像装置 |
| DE4334038C1 (de) * | 1993-10-06 | 1995-03-23 | Bruker Medizintech | Geräuscharmes NMR-Bildgebungsverfahren mit Einzelpunktaufnahme (SPI) |
| US20060155186A1 (en) * | 2005-01-12 | 2006-07-13 | James Timothy W | Bone health assessment using spatial-frequency analysis |
| BRPI0619008A2 (pt) * | 2005-11-27 | 2011-09-20 | Osteotronix Ltd | método para avaliar pelo menos uma caracterìstica de uma amostra de uma estrutura e método para avaliar estruturas ósseas |
| US7602180B2 (en) * | 2006-11-02 | 2009-10-13 | Siemens Aktiengesellschaft | System and method for fast texture-based tensor field visualization for DT-MRI |
| DE102011007501B3 (de) * | 2011-04-15 | 2012-05-31 | Universitätsklinikum Freiburg | Verfahren der bildgebenden Magnetresonanz zur Selektion und Aufnahme von gekrümmten Schichten |
| JP2014526339A (ja) * | 2011-09-13 | 2014-10-06 | アキュイタス・メディカル・リミテッド | アルツハイマー病及び関連する病態の特徴を検知するための方法 |
| US9360542B2 (en) * | 2012-04-20 | 2016-06-07 | Wisconsin Alumni Research Foundation | System and method for spectrally-resolved three-dimensional magnetic resonance imaging without frequency-encoding gradients |
| US9664759B2 (en) | 2014-09-01 | 2017-05-30 | bioProtonics, L.L.C | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling |
| AU2015312190A1 (en) * | 2014-09-01 | 2017-03-23 | Bioprotonics, Inc. | Selective sampling magnetic resonance-based method for assessing structural spatial frequencies |
-
2016
- 2016-10-07 AU AU2016334250A patent/AU2016334250B2/en active Active
- 2016-10-07 WO PCT/US2016/056147 patent/WO2017062882A1/fr active Application Filing
- 2016-10-07 EP EP16854502.8A patent/EP3359034A4/fr active Pending
- 2016-10-07 CN CN201680071304.4A patent/CN108366753B/zh active Active
- 2016-10-07 JP JP2018517540A patent/JP6906507B2/ja active Active
- 2016-10-07 CA CA3000765A patent/CA3000765C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3359034A4 (fr) | 2019-08-07 |
| JP2018529474A (ja) | 2018-10-11 |
| AU2016334250B2 (en) | 2020-04-02 |
| JP6906507B2 (ja) | 2021-07-21 |
| CN108366753A (zh) | 2018-08-03 |
| AU2016334250A1 (en) | 2018-05-17 |
| CN108366753B (zh) | 2019-06-07 |
| CA3000765C (fr) | 2024-01-23 |
| WO2017062882A1 (fr) | 2017-04-13 |
| EP3359034A1 (fr) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3000765C (fr) | Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques | |
| US11175363B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| US9664760B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| AU2021201998B2 (en) | Selective sampling magnetic resonance-based method for assessing structural spatial frequencies | |
| US9664759B2 (en) | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling | |
| Charles-Edwards et al. | Diffusion-weighted magnetic resonance imaging and its application to cancer | |
| US11353533B2 (en) | Methods and devices for contrast agent magnetic resonance imaging | |
| JP7273803B2 (ja) | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング | |
| US10215827B2 (en) | Method to measure tissue texture using NMR spectroscopy to identify the chemical species of component textural elements in a targeted region of tissue | |
| Horie et al. | Magnetic resonance imaging technique for visualization of irregular cerebrospinal fluid motion in the ventricular system and subarachnoid space | |
| Andronesi et al. | Whole brain mapping of water pools and molecular dynamics with rotating frame MR relaxation using gradient modulated low-power adiabatic pulses | |
| AU2018297168A1 (en) | A method to measure tissue texture using NMR spectroscopy to identify chemical species of component textural elements in a targeted region of tissue | |
| Nunes et al. | Diffusion mri outside the brain | |
| Habib | Development & optimization of diffusion tensor imaging at high field strengths in translational research | |
| Sperling et al. | Diffusion-Weighted Whole-Body Imaging: Tumor Staging Applications | |
| Takahara et al. | MR neurography: imaging of the peripheral nerves | |
| Marx | Improved MRI Thermometry for MR-Guided Focused Ultrasound in the Brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |
|
| EEER | Examination request |
Effective date: 20211004 |